Gastrogel

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gastrogel

Quick Facts

Property Description
Active Ingredient Sucralfate
Form Oral Suspension, Tablet
Pharmacological Class Anti-ulcer Agent, Cytoprotective
Route of Administration Oral
Origin Synthetic (Sucrose-derived)

What Type of Medicine is Gastrogel (Sucralfate)?

Gastrogel is a prescription-only medication primarily used for the management of upper gastrointestinal disorders, with its core identity rooted in the active substance Sucralfate. It is classified as a gastrointestinal agent, specifically a cytoprotective and anti-ulcer medication, used to provide a physical shield to the lining of the digestive tract. This classification is clinically recognized for its distinction from acid-reducing therapies.

Composition and Forms of Gastrogel

The chemical basis of this medicine is Sucralfate, which is chemically an aluminum hydroxide sucrose sulfate complex. This unique structure allows it to function differently than traditional acid reducers. Sucralfate's mechanism is fundamentally non-systemic; it has minimal systemic absorption. The medicine is administered orally and is available in common dosage forms including a liquid oral suspension and a tablet. The oral suspension is often favored when there is a need for the medicine to uniformly cover the internal mucosal surface.

General Purpose of Cytoprotective Agents

The primary purpose of Sucralfate is to provide effective localized defense through cytoprotection. When exposed to stomach acid, the compound transforms into a sticky substance that adheres selectively and strongly to proteins exposed at the site of mucosal injuries. This selective binding creates a durable, physical protective barrier over the damaged tissue. This mechanism shields the sensitive areas from destructive agents, including hydrochloric acid and pepsin, thereby creating a localized environment conducive to the body’s natural regenerative and repair processes. Sucralfate's therapeutic role is established by its ability to prevent the worsening of ulcerations, supporting its classification as an effective anti-ulcer therapy.

Regulatory References

  1. Sucralfate: MedlinePlus Drug Information
  2. Sucralfate - StatPearls - NCBI Bookshelf

What side effects are possible with Gastrogel?

Possible Side Effects and Safety Information

The safety characteristics of Gastrogel (Sucralfate) are derived from official regulatory documentation, which organizes adverse reactions by frequency and physiological system. The most common adverse reaction documented in clinical regulatory data is constipation. Other reactions that are officially classified as uncommon may include dry mouth and nausea, reflecting the medicine's primary action within the gastrointestinal tract.

Official System-Organ Classes Affected

Adverse effects are formally categorized into system-organ classes, including:

Classification Examples of Documented Reactions
Gastrointestinal Disorders Constipation, dry mouth, diarrhea, nausea, vomiting
Nervous System Disorders Dizziness, sleepiness, insomnia
Skin and Subcutaneous Rash, itching (pruritus)

Serious Adverse Reactions and Population Constraints

Official regulatory sources note the potential for serious adverse reactions, including the formation of a compact mass known as a bezoar (intestinal obstruction), particularly in patients with predisposing conditions. The safety profile also includes specific constraints for certain populations due to the aluminum component of Sucralfate.

Caution is officially advised for patients with chronic renal failure and older adults, as they are at an increased risk of aluminum accumulation and toxicity, which may manifest as encephalopathy (a brain disorder) with prolonged use. Furthermore, the official label includes the critical restriction that the oral suspension must be administered only by the oral route, as inappropriate intravenous use has been associated with fatal complications.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Scope

Gastrogel is an antacid medication, typically containing active ingredients such as aluminium hydroxide. While an overdose from this class of medication is uncommon in individuals with normal kidney function, an excessive intake can disrupt the body’s normal balance of electrolytes.

Classification Area Official Regulatory Context
Documented Overdose Presentation No specific, distinct clinical syndrome is widely cited for an acute single large overdose in official documents.
Physiological Systems Affected High concentrations of the active ingredients, particularly magnesium, can affect the central nervous system, cardiovascular system, and muscles.
Dose/Exposure Factors Risk of toxicity is significantly increased in individuals with impaired renal function due to the reduced ability to eliminate aluminium and magnesium from the body.
Population-Specific Overdose Notes Special caution is required in the context of paediatric use or in patients with pre-existing kidney disease, where monitoring may be necessary.

Clinical Manifestations of Excessive Intake

Symptoms associated with severe or prolonged excessive intake, especially in susceptible individuals, include signs of high aluminium or magnesium levels. High magnesium levels (hypermagnesemia) can manifest as drowsiness, muscle weakness, confusion, slow or irregular heartbeat, and low blood pressure. High aluminium exposure, particularly over a prolonged period, is linked to systemic toxicity in patients with renal impairment.

When Immediate Medical Help is Required

Urgent medical attention is necessary if an exceptionally large amount of the medicine is ingested, or if any severe symptoms, such as significant muscle weakness, confusion, or severe drowsiness, are experienced. Contacting a poison control center or seeking emergency medical help should be the first action in the event of a suspected overdose.

Therapeutic Uses of Gastrogel

Quick Facts

  • Therapeutic Domain: May help manage conditions related to excess stomach acid.
  • Primary Uses: Aims to provide symptomatic relief from heartburn and acid indigestion.
  • Supportive Use: Used for the temporary management of symptoms associated with gastroesophageal reflux disease (GERD).

Gastrogel is a medication formulated to address gastrointestinal discomfort by supporting the neutralization of stomach acid. It is primarily utilized for the symptomatic relief of heartburn and acid indigestion (sour stomach) when these conditions cause temporary discomfort.

The compound is also indicated for the management of symptoms related to gastroesophageal reflux disease (GERD). By modulating gastric acidity, Gastrogel helps to alleviate the associated burning sensation and discomfort in the upper abdomen and esophagus. The therapeutic approach may also support the care plan for individuals with gastric or duodenal ulcers by mitigating the aggressive factors of stomach acid.

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Gastrogel?

Eligibility for Gastrogel (Aluminium Hydroxide and Magnesium Trisilicate) is strictly defined by regulatory documents, focusing on conditions that affect the body's ability to process its metallic components.

Contraindications (Who Must Not Use):

Population/Condition Restriction Basis
Severe Renal Failure Risk of Magnesium and Aluminium accumulation (hypermagnesemia).
Known Hypersensitivity Allergy to Aluminium Hydroxide, Magnesium Trisilicate, or any components.
Hypophosphatemia Risk Patients on very low phosphate diets due to Aluminum's phosphate-binding effect.

Populations Requiring Conditional Use:

  • Non-Severe Renal Impairment: Use requires caution and may be limited to prevent accumulation; professional supervision is necessary.
  • Children Under 12 Years: Use is generally not recommended as safety and efficacy have not been formally established in this age group.
  • Pregnancy/Lactation: Use should be approached with caution and only if the treating professional determines the benefit outweighs the potential risk, as formal data may be insufficient.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Gastrogel (Sucralfate) is defined by its non-systemic mechanism of action and its aluminum content.


Interaction Scope and Restrictions

The primary, clinically significant interaction involves the reduced extent of absorption (bioavailability) of several co-administered medicinal products. These include Cimetidine, Digoxin, Fluoroquinolone antibiotics, Ketoconazole, Levothyroxine, Phenytoin, Ranitidine, and Theophylline. This effect is officially attributed to the non-systemic binding of Sucralfate to these agents within the gastrointestinal tract. To mitigate this pharmacokinetic interference, regulatory documents mandate a timing separation: affected systemically-absorbed medications must be administered two hours before Gastrogel.

The combination of Gastrogel with Citrate preparations is classified as a contraindicated combination because citrates significantly increase the absorption and plasma concentration of the aluminum component in Sucralfate, raising the risk of systemic aluminum toxicity. Co-administration with other aluminum-containing products (e.g., antacids) requires a minimum of one half-hour separation to manage the total body aluminum burden.


Population-Specific Notes

The risk of aluminum accumulation and toxicity is officially heightened in patients with Chronic Renal Failure and those on Dialysis due to documented impaired aluminum excretion. This enhanced risk extends to Elderly Patients due to the higher likelihood of age-related decreased renal function, necessitating caution.

Mechanism of Action

Antacid: Chemical Neutralization and pH Modulation

The drug's primary action is the chemical neutralization of hydrochloric acid (HCl) already present in the stomach, directly raising the gastric fluid's pH level . This molecular reaction modulates the highly acidic chemical environment, resulting in a rapid increase in pH within the digestive lumen.


Enzymatic Inhibition via Environmental Shift

The resulting increase in pH initiates a critical downstream effect: the inactivation of pepsin. By moving the gastric environment outside of pepsin's optimal low- pH range, the enzyme's structure changes, leading to a significant reduction in its activity. This pH-dependent change reduces the enzyme's proteolytic activity, which limits its capacity to act upon the mucosal tissue.


Localized Mucosal Barrier Reinforcement

Active components also contribute to the mucosal defense system. They physically adhere to the stomach lining, potentially forming a protective coating, and biochemically stimulate the release of factors such as bicarbonate. This action promotes the reinforcement of the gastric barrier, which increases local resistance to chemical and mechanical factors.

Dosage and Administration Information

How to Use Gastrogel (Sucralfate)

The usage of Gastrogel (Sucralfate) is defined by a strict, time-conditional oral administration protocol.

Administration Scope

Instruction Detail
Route of Administration Oral only. The suspension must not be administered intravenously.
Dosing Schedule Acute Ulcer Treatment: 1 gram four times daily (QID).
Maintenance Therapy: 1 gram twice daily (BID).
Timing in relation to meals Must be administered on an empty stomach, typically 1 hour before each meal and at bedtime.
Preparation Requirements The oral suspension must be thoroughly shaken before each use. Tablets may be dispersed in a small volume of water.
Age-Group Administration Older Adults: Dose selection should be cautious, generally starting at the low end of the dosing range.
Pediatrics: Safety and efficacy have not been established.
Special Procedural Conditions Antacids: Must not be taken within one-half hour before or after Gastrogel.
Other Oral Medications: Should be separated from Gastrogel by 2 hours.
Course Duration Acute Treatment: 4 to 8 weeks, continued until ulcer healing is confirmed.
Maintenance Therapy: Up to 12 months in certain regions.

Official Step Sequence

  1. Administer the prescribed 1-gram dose (tablet or suspension) via the oral route.
  2. Take the dose on an empty stomach at the designated times (e.g., 1 hour before meals).
  3. Ensure the dose is separated from other oral medications by a 2-hour interval.
  4. Continue the regimen for the specified duration (e.g., 4 to 8 weeks) based on the treatment phase.

This structured protocol emphasizes precise timing and separation from food and other agents.

Recent Clinical Evidence

Research evidence / Overview of Studies for Gastrogel (Sucralfate)

This overview describes what has been learned about Gastrogel's use in various conditions based on official, independent research.


The core research on Gastrogel (sucralfate) involves Randomized Controlled Trials (RCTs) and controlled studies examining the short-term management of active duodenal ulcers in adults. Researchers primarily focused on the rate of ulcer healing, which was typically confirmed by endoscopy, and changes in patient-reported symptoms like pain. Trials also explored this agent as a maintenance therapy, monitoring ulcer recurrence rates over periods up to one year. A key contextual limitation is that much of this foundational evidence predates the widespread understanding and treatment of the H. pylori bacterium, meaning the available data may not fully reflect modern care protocols that prioritize H. pylori eradication.

Research has also explored the use of this agent in specific settings, such as critically ill adults in the Intensive Care Unit (ICU). Systematic reviews and comparative RCTs monitored high-stakes outcomes like the incidence of clinically important gastrointestinal (GI) bleeding. Evidence quality varies across these trials, and comparative evidence is often lacking for patients who require intravenous methods of prophylaxis, as this agent is administered orally.

Studies have investigated this agent in symptomatic Gastroesophageal Reflux Disease (GERD), measuring changes in heartburn intensity and esophageal healing rates over short-term intervals. The research for GERD is generally older and more limited. Consequently, comparisons against other widely used agents in long-term management are not fully characterized in the available evidence. Overall, research highlights that long-term effects are not fully established, and data remains insufficient for specific patient subgroups.

Frequently Asked Questions (FAQ)

Common questions about Gastrogel (FAQ)


Q: Is Gastrogel considered an antacid?

Gastrogel is primarily classified by regulatory agencies as a cytoprotective anti-ulcer agent. Its mechanism of action does include a local, chemical neutralizing effect on existing stomach acid, which provides some acid-neutralizing capacity. This means it acts differently than medicines that stop your body from making acid, such as proton pump inhibitors (PPIs).


Q: How quickly does Gastrogel start to work?

Studies and official information indicate that the drug’s initial onset of action when used for peptic ulcer disease is typically within 1 to 2 hours after administration. This reflects the time it takes for the substance to react with stomach acid and form the protective barrier.


Q: How long does the effect of Gastrogel last?

Official data indicates that the local protective effect of a single dose on the ulcer site lasts for approximately 6 hours. This duration is due to the substance’s strong adhesion to the damaged mucosal tissue.


Q: Does Gastrogel expire, and how long is it good for after opening?

Like all medicines, Gastrogel is assigned an expiration date based on formal stability studies defining the conditions under which its integrity is maintained. For instance, regulatory reviews have supported an expiration date of up to 24 months. However, the official labeling does not consistently detail the shelf life or stability of the product after it has been opened for the first time.


Q: Is Gastrogel gluten-free or suitable for people with allergies?

Official product information states that known hypersensitivity (allergy) to the active substance or any of the inactive ingredients, also called excipients, is a contraindication (formally advised against). Regulatory documents do not explicitly classify the product as gluten-free.


Q: Are there any major diet changes required while taking Gastrogel?

No specific foods are reported to chemically interact with Gastrogel. The official administration protocol requires the medication be taken on an empty stomach, typically 1 hour before a meal, to support the intended coating effect.


Q: What are the signs of an allergic reaction to Gastrogel?

Official post-marketing reports of hypersensitivity (allergic) reactions have included serious symptoms. These symptoms can include hives, rash, itching, swelling of the face, lips, tongue, or throat, and difficulty breathing.


Q: Does Gastrogel interact with blood pressure medication?

Gastrogel can reduce the absorption of many co-administered systemically-absorbed medicines because it binds to them locally in the gut. To help minimize this potential interference, regulatory documents specify that affected medications should be administered two hours before Gastrogel.


Q: Can I take Gastrogel at the same time as my vitamins?

Official documents specify a two-hour interval between Gastrogel and other oral medications to help minimize potential interference with the co-administered agent's absorption. This is because Gastrogel's local binding action can reduce the amount of the other agent absorbed in the gut.


Q: Is there a risk of taking Gastrogel with pain relievers like ibuprofen?

Regulatory labeling advises separating Gastrogel from other oral medications by two hours. This practice is in place to help prevent the potential reduced absorption of the co-administered medication. Ibuprofen is not explicitly listed in all official documents as an interacting agent.


Q: Is Gastrogel a proton pump inhibitor (PPI)?

No, Gastrogel (Sucralfate) is not a proton pump inhibitor (PPI). It is classified as a cytoprotective agent that works by coating the ulcer site. It helps heal existing damage and does not stop your stomach from producing acid, which is how PPIs work.


Q: Does Gastrogel contain aluminum or magnesium?

The active ingredient, Sucralfate, is chemically an aluminum hydroxide sucrose sulfate complex, meaning it contains aluminum. The tablet formulation may also contain inactive ingredients, or excipients, such as magnesium stearate.


Q: Is it normal to feel bloated after taking Gastrogel?

Official regulatory documents report that some patients may experience rare or less common gastrointestinal adverse effects. These effects include a feeling of fullness or flatulence (passing gas), which are symptoms a user might interpret as bloating.


Q: Can Gastrogel mask symptoms of a more serious condition?

The official label specifies that the healing of duodenal ulcers must be confirmed by diagnostic methods, such as x-ray or endoscopic examination, after treatment. This requirement supports reliance on diagnostic testing beyond symptom relief alone.


Q: How is Gastrogel described in official drug information leaflets?

Official leaflets provided by regulatory agencies use formal, technical language to describe the product. They include details on the drug’s chemical structure, its detailed clinical pharmacology (how it works), and its official therapeutic category (anti-ulcer agent).


Q: Is Gastrogel known to cause headaches?

Official adverse reaction reports classify headache as an effect reported in less than 0.5% of patients during clinical trials. It is not listed as one of the most common adverse effects documented for the medication.


Q: Are there different strengths or formulations of Gastrogel?

Official regulatory documents define the product as being formally available in a 1 gram tablet form and a 1 gram/10 mL oral suspension. No other dosage strengths are typically listed in the official labeling.


Q: Why do some people say Gastrogel stops working after a while?

Regulatory documents note that duodenal ulceration is naturally a recurrent disease. The short-term treatment with Gastrogel is not expected to change the frequency or severity of future ulcer episodes that may occur after the initial treatment course is complete.


Q: Can Gastrogel be split or crushed if it's a tablet?

Official prescribing information indicates that the tablet form may be dispersed in a small amount of water to aid administration. Some references mention that while the tablets do not crush well, they may be split for preparation.


Q: Does Gastrogel have any effect on mineral absorption?

Sucralfate is known to have a phosphate-binding effect, which creates a risk for patients with low phosphate levels (hypophosphatemia). The drug's local binding action in the gut can also reduce the absorption of other co-administered agents.


Q: Are there any clinical trials involving adolescents and Gastrogel?

Official regulatory documents state that the safety and effectiveness of Gastrogel have not been established in pediatric patients. This patient group typically includes the adolescent age range.


Q: Do regulatory agencies classify Gastrogel as a high-risk medication?

While the drug is not generally classified as high-risk, official labeling includes a WARNING regarding the serious potential for fatal complications. These risks occur if the oral suspension is administered through the intravenous (IV) route, as the product is approved only for the oral route.

How should Gastrogel be stored and disposed of?

Storage and Disposal of Gastrogel (Sucralfate)

Gastrogel (Sucralfate) must be stored and handled according to specific conditions defined in regulatory labeling to ensure its integrity and safety.


Storage Requirements

  • Temperature: Store at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F). The oral suspension form must not be frozen as freezing can affect its stability.
  • Protection: The medication must be protected from moisture, heat, and direct light.
  • Container: Keep the product in its original container with the lid tightly closed.
  • Child Safety: All forms of the medicine must be stored out of the reach of children.

Disposal Instructions

  • General Rule: Unused or expired Gastrogel must be discarded following local government regulations.
  • Restriction: It should not be flushed down a toilet or poured down a drain. Utilize a drug take-back program or follow FDA guidelines for household trash disposal if no take-back option is available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gastrogel found in:

A-Z Index: